The global medical aesthetics market, valued at US$15.59 billion in 2023, is forecasted to grow at a robust CAGR of 12.8%, reaching US$17.16 billion in 2024 and an impressive US$35.32 billion by 2030.

The global medical aesthetics market, valued at US$15.59 billion in 2023, is forecasted to grow at a robust CAGR of 12.8%, reaching US$17.16 ...

The U.S. dermal fillers market thrives with hyaluronic acid driving demand, projecting a 36% CAGR due to rising popularity of injectables and cosmetic treatment Ankush Nikam Future Market Insights, ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. If you ...

The European Medicines Agency’s human medicines committee has recommended Galderma’s nemolizumab to treat atopic dermatitis ...

As a trusted companion for first-time moms, Cetaphil Baby recently held an intimate and educational event aimed at building ...

The report furnishes an intricate comprehension of each segment, delivering potential estimations for principal applications and insights into emerging prospects. Every regional market is meticulously ...

Switzerland’s Galderma has won US Food and Drug Administration (FDA) approval for the use of Nemluvio (nemolizumab) for ...

The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.

This highly anticipated drug is expected to become a key treatment for prurigo nodularis and atopic dermatitis. Galderma’s midterm targets for the period 2023 to 2027 are for low- to mid-teens ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of. Ms. Kalofonos will lead the company’s commercial strategy and operations for the potential launch of paltusotine, the ...

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD).